Roivant Sciences (ROIV) Q3 2025 earnings review
Clinical Breakthrough Overshadows Widening Losses
Roivant delivered a definitive clinical victory in Q3 with its Brepocitinib data, showing a massive efficacy delta against placebo in Cutaneous Sarcoidosis. While the pipeline delivered, the P&L showed strain: Net Loss from continuing operations widened 50% YoY to $314M, driven by rising R&D costs and a $17M headquarters impairment charge. However, with a massive $4.5 billion cash pile, the burn rate remains a secondary concern to the value-creation engine of the pipeline.
🐂 Bull Case
The Phase 2 BEACON study for brepocitinib was a homerun. The drug achieved a 22.3-point improvement in disease activity vs just 0.7 for placebo (p<0.0001). This opens a clear path to a pivotal Phase 3 program in 2026.
Roivant holds $4.5 billion in cash and securities. Even with increased burn, this provides years of runway and negotiation leverage without the need for dilutive financing.
🐻 Bear Case
G&A expenses spiked 24% YoY to $175M, driven by a $17M impairment loss on an HQ move and rising stock-based compensation ($87M vs $69M YoY). Efficiency is dragging.
Revenue fell to just $2.0M from $9.0M YoY following the Dermavant divestiture. The company is purely a spend-driven R&D shop until commercial launches materialize.
⚖️ Verdict: 🟢
Bullish. For a biotech, clinical data is currency, and Roivant just printed a fortune with the BEACON results. The widening loss is expected as trials advance, and the $4.5B cash position creates a safety net that few peers possess.
Key Themes
Brepocitinib: A New Standard in Cutaneous Sarcoidosis
The BEACON study results are undeniably strong. Brepocitinib 45mg achieved a 22.3-point reduction in the CSAMI-A activity score, compared to a negligible 0.7 reduction for placebo. Furthermore, 100% of patients in the high-dose arm achieved clinically meaningful improvement (>10 points) versus only 14% on placebo. This validates the mechanism and de-risks the upcoming Phase 3 program.
Moderna Litigation Timeline Locked
The patent infringement trial against Moderna is scheduled for March 2026. This remains a massive 'lottery ticket' catalyst. With favorable summary judgment proceedings ongoing, a settlement or win could bring non-dilutive capital in the billions, given the scale of COVID-19 vaccine revenues involved.
G&A Blowout & Real Estate Impairment
General & Administrative expenses jumped to $175.1M (Accelerating). A significant portion was a $17.1M impairment charge related to relocating the U.S. headquarters. While one-time, it flags operational friction. More concerning is the structural rise in share-based compensation, which hit $86.9M in G&A alone, up from $69.4M last year.
IMVT-1402 Velocity
Immunovant (Roivant's subsidiary) fully enrolled its potentially registrational trial for IMVT-1402 in rheumatoid arthritis. With a $550M financing completed to extend runway, the focus shifts to execution, with topline data expected in H2 2026.
Pipeline Concentration Risk
With Dermavant sold, the narrative rests heavily on Brepocitinib and Immunovant. Any clinical stumble in these late-stage assets (like the upcoming NIU Phase 3 in H2 2026) would have magnified impact on valuation compared to a more diversified commercial stage company.
Other KPIs
Stable. The war chest remains massive, supporting a 'cash runway into profitability.' This figure excludes potential upside from litigation or future milestones from the Dermavant sale ($950M potential).
Accelerating (+17% YoY). The increase is driven by program-specific costs for mosliciguat (+$5.7M) and brepocitinib (+$5.3M). This is 'good' spending, reflecting late-stage trial progression rather than overhead bloat.
Decelerating performance (Widening Loss). Loss deepened from $208.9M a year ago. On a per-share basis, the loss widened to $0.38 from $0.22, reflecting the heavy investment phase Roivant is currently navigating.
Guidance
Stable timeline. Topline data for Non-Infectious Uveitis is expected in the second half of 2026. This is a critical readout following the CS success.
Stable. The date is set. This binary event is a major Q1/Q2 2026 catalyst.
Approaching. Data for Thyroid Eye Disease is expected in the first half of the year. Positive results could trigger immediate repricing of the Immunovant franchise.
Stable. Trial is fully enrolled. This reads out in the second half of the year, adding another shot on goal for the pipeline.
Key Questions
Brepocitinib Commercial Strategy
With the BEACON data being so strong, are you exploring a standalone launch for Cutaneous Sarcoidosis, or is the strategy to bundle the launch with Dermatomyositis and Uveitis to optimize sales force efficiency?
G&A Run Rate
G&A hit $175M this quarter. Excluding the $17M impairment, expenses are still structurally higher. Is this the new baseline for G&A as you prepare for commercialization, or should we expect this to retract?
Litigation Settlement Appetite
With the trial date in March 2026 firmly set, has the company's appetite for a pre-trial settlement changed, or are you fully committed to taking this to a jury verdict?